← Back

Wire · opportunities

QurAlis Receives FDA Clearance for IND Application of QRL-201 for the Treatment of ALS ...

Published

16 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at businesswire.com →

◆ Verified

Fusion42 · 16 November 2026 · Fusion42 review

QurAlis has received FDA clearance for the IND application of QRL-201, a first-in-class antisense oligonucleotide therapeutic targeting ALS, enabling it to initiate a pivotal clinical trial in the U.S. The ANQUR clinical trial's final data demonstrated that QRL-201 significantly slowed ALS progression by 50% and reduced key biomarkers of axonal damage, showing promise for modifying disease outcomes.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 16 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You now have a clear regulatory path to run a pivotal ALS trial in the U.S. Moving fast to prepare for the 2027 CONQUR trial start date will put you ahead in precision ALS therapeutics.

◆ Coverage

3 sources · first reported 16 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDA-clearanceALS-treatmentclinical-trialantisense-therapyQRL-201